TrivarX (TrivarX) Debt-to-Asset : 0.01 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is TrivarX Debt-to-Asset?

TrivarX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. TrivarX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. TrivarX's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $6.30 Mil. TrivarX's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

TrivarX Debt-to-Asset Historical Data

The historical data trend for TrivarX's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Debt-to-Asset Chart

TrivarX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.21

0.01

TrivarX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															-	0.01	-	0.01	0.01

Competitive Comparison of TrivarX's Debt-to-Asset

For the Health Information Services subindustry, TrivarX's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TrivarX's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where TrivarX's Debt-to-Asset falls into.

TrivarX Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

TrivarX's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.074	+	0)	/	5.391
	=	0.01

TrivarX's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.041	+	0)	/	6.297
	=	0.01

TrivarX (OTCPK:MDBIF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

TrivarX Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of TrivarX's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

TrivarX (TrivarX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (OTCPK:MDBIF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

TRI:Australia

Address

647 Beaufort Street, Mount Lawley, WA, AUS, 6050

Website

https://www.medibio.com.au

TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.